Neurogene Inc.
Business
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines to treat complex neurological diseases using its proprietary transgene regulation platform, EXACT. It offers gene therapy product candidates and discovery programs, including an EXACT-regulated MECP2 replacement program for Rett syndrome and a conventional gene therapy program for CLN5 Batten disease, along with in-house cGMP manufacturing and CMC capabilities. Key business activities include research and development, clinical trials, manufacturing, and intellectual property licensing. The company conducts clinical development and early-stage trials across multiple regions and plans commercialization through internal infrastructure and external partnerships.
Summary from filing dated 2025-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue under licensing agreements | 0 | 925,000 | 0 | — | — | |
| Research and development expenses | 75 | 61 | 44 | 48 | 39 | |
| General and administrative expenses | 28 | 23 | 11 | 9 | 22 | |
| Total operating expenses | 103 | 84 | 56 | 57 | 61 | |
| Loss from operations | −103 | −83 | −56 | −57 | −61 | |
| Interest income | 12 | 8 | 3 | 1 | — | |
| Interest expense | −5,000 | −12,000 | −12,000 | — | — | |
| Other income | 2 | 574,000 | 16 | — | — | |
| Other expense | −230,000 | −2 | −28,000 | −7,000 | — | |
| Net loss | −90 | −75 | −36 | −55 | −61 | |
| Net loss per share, basic (in dollars per share) | −4.24 | −4.28 | — | −1.04 | −1.1 | |
| Net loss per share, diluted (in dollars per share) | −4.24 | −4.28 | — | −1.04 | −1.1 | |
| Weighted-average shares of common stock outstanding, basic (in shares) | 21 | 18 | — | 55 | 55 | |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 21 | 18 | — | 55 | 55 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 104 | 137 | 148 | 82 | 142 | |
| Short-term investments | 165 | 176 | 49 | 0 | 0 | |
| Prepaid expenses and other current assets | 3 | 4 | 3 | 3 | — | |
| Total current assets | 272 | 316 | 200 | 85 | 144 | |
| Property and equipment, net | 13 | 15 | 17 | 20 | — | |
| Operating lease right-of-use assets | 3 | 3 | 4 | 4 | 11 | |
| Finance lease right-of-use assets | 22,000 | 71,000 | 98,000 | 87,000 | — | |
| Restricted cash | 339,000 | 339,000 | 508,000 | 0 | — | |
| Other non-current assets | 1 | 975,000 | 764,000 | 0 | 2 | |
| Total assets | 289 | 336 | 223 | 109 | 163 | |
| Accounts payable | 2 | 1 | 3 | 625,000 | — | |
| Accrued expenses and other current liabilities | 11 | 10 | 17 | 5 | — | |
| Operating lease liabilities, current | 3 | 3 | 3 | 678,000 | 1 | |
| Finance lease liabilities, current | 14,000 | 54,000 | 42,000 | 24,000 | 55,000 | |
| Contingent value rights liability, current | 638,000 | 1 | 281,000 | 0 | — | |
| Total current liabilities | 16 | 15 | 23 | 7 | 9 | |
| Operating lease liabilities, non-current | 7 | 9 | 12 | 4 | 12 | |
| Finance lease liabilities, non-current | 5,000 | 26,000 | 65,000 | 66,000 | 67,000 | |
| Contingent value rights liability, non-current | 428,000 | 718,000 | 1 | 0 | — | |
| Other liabilities | 51,000 | 51,000 | 203,000 | 0 | — | |
| Total liabilities | 24 | 25 | 37 | 11 | 20 | |
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Additional paid-in capital | 618 | 573 | 373 | 5 | 536 | |
| Accumulated deficit | −353 | −262 | −187 | −151 | −393 | |
| Total stockholders' equity | 265 | 310 | 186 | −146 | −92 | |
| Total liabilities and stockholders' equity | 289 | 336 | 223 | 109 | 163 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 14 | 8 | 1 | 1 | 12 | |
| Depreciation and amortization of property and equipment | 3 | 3 | 3 | 3 | 1 | |
| Asset impairment | 120,000 | 91,000 | 0 | — | — | |
| Non-cash operating lease expense | 800,000 | 741,000 | 663,000 | 608,000 | — | |
| Amortization of finance lease right-of-use assets | 49,000 | 52,000 | 35,000 | 4,000 | — | |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | −5 | −2 | −105,000 | 0 | 0 | |
| Change in contingent value rights liability | −743,000 | 522,000 | 0 | — | — | |
| Gain on lease modification | −6,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 952,000 | −327,000 | 326,000 | 716,000 | — | |
| Other assets | −58,000 | −211,000 | −764,000 | 0 | 129,000 | |
| Accounts payable | 627,000 | −77,000 | 667,000 | −4 | — | |
| Accrued expenses and other liabilities | 2 | −3 | −4 | 806,000 | — | |
| Operating lease liabilities | −3 | −3 | −678,000 | −610,000 | −687,000 | |
| Net cash used in operating activities | −77 | −71 | −51 | −53 | −48 | |
| Purchases of property and equipment | −1 | −808,000 | −321,000 | −2 | −3 | |
| Purchases of held-to-maturity investments | −270 | −198 | 0 | — | — | |
| Proceeds from maturities of held-to-maturity investments | 285 | 74 | 5 | 0 | — | |
| Net cash provided by (used in) investing activities | 14 | −125 | 26 | −2 | −3 | |
| Payment of deferred offering costs related to at-the-market sales agreement | −241,000 | 0 | — | — | 0 | |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | 30 | 0 | 92 | 0 | 0 | |
| Offering costs in connection with pre-closing financing | 0 | −4 | 0 | — | — | |
| Transaction costs related to reverse merger | 0 | −3 | 0 | — | — | |
| Proceeds from the issuance of common stock upon exercise of options | 266,000 | 2 | 168,000 | 73,000 | 411,000 | |
| Proceeds from private financing, net of offering costs paid | 0 | 190 | 0 | — | — | |
| Principal payments on finance leases | −61,000 | −52,000 | −29,000 | −1,000 | −51,000 | |
| Proceeds from the issuance of common stock under Employee Stock Purchase Plan | 84,000 | 0 | — | 82,000 | 372,000 | |
| Net cash provided by financing activities | 30 | 184 | 92 | 67 | 732,000 | |
| Net decrease in cash, cash equivalents and restricted cash | −33 | −12 | 67 | 11 | −50 | |
| Additions to operating lease right of use assets from new operating lease liabilities | 0 | 60,000 | 0 | 0 | 2 | |
| Property and equipment included in accounts payable and accrued expenses | 76,000 | 726,000 | 0 | 283,000 | 412,000 | |
| Additions to finance lease right of use assets from new finance lease liabilities | 0 | 25,000 | 46,000 | 91,000 | 0 | |
| Offering costs related to private offering, included in accounts payable and accrued expenses | 0 | 90,000 | 0 | — | — | |
| Cash paid for interest | 5,000 | 12,000 | 12,000 | 2,000 | — | |
| Deferred offering costs reclassified to additional paid-in capital | 50,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Neurogene Inc.'s CIK number?
Neurogene Inc.'s SEC CIK number is 0001404644 (1404644). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Neurogene Inc.'s SEC filings?
All of Neurogene Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Neurogene Inc. last report earnings?
Neurogene Inc. (NGNE) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001404644-26-000038). This is Neurogene Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Neurogene Inc.'s most recent earnings 8-K?
Neurogene Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001404644-26-000038. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Neurogene Inc.'s latest earnings 8-K →
Look up any company's CIK number →